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Abstract
Background: The quality control of oral anticoagulant therapy (OAT) during the initiation and maintenance treatment
is generally poor. Physicians' ordering of OAT (especially fluindione and warfarin) can be improved by dose adjustment
algorithms, taking into account the results of International Normalized Ratio (INR). Reminders at the point of care,
computerized or not, have been demonstrated to be effective in changing physicians prescription behavior.
However, few studies have addressed the benefit of personalized reminders versus non personalized reminders, whereas
the personalized reminders require more development to access patient record data and integrate with the
computerized physician order entry system.
The Hospital Information System of George Pompidou European Hospital integrates an electronic medical record, lab
test and drugs order entry system. This system allows to evaluate such reminders and to consider their implementation
for routine use as well as the continuous evaluation of their impact on medical practice quality indicators.
The objective of this study is to evaluate the impact of two types of reminders on overtreatment by oral anticoagulant:
a simple reminder of text formatted dose adjustment table and a personalized recommendation for oral anticoagulant
dose and next date of INR control, adapted to patient data. Both types of reminders appear to the physician at the
moment of drug ordering.
Methods: The study is an alternating time series experiment with three 6 months periods, each one including every 2
months according to a Latin square scheme: a control period without any reminder, a period with the simple non
personalized reminder, a period with personalized reminder. All patients hospitalized in departments using the
computerized physician order entry system and ordered fluindione or warfarin, will be included in the study between
November 2004 and May 2006.
Main outcome will be the proportion of overcoagulation, as expressed by the proportion of observation time with INR
over 4.5, assuming INR change linearly. Secondary outcome is the incidence of major haemorrhagic events. Data will be
collected thanks to Hospital Information Systems databases.
Data will be analyzed taking into account patient and physician clustering effect.
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Background
Iatrogenic effects of oral anticoagulants therapy
According to a study carried out by French pharmacovigi-
lance centres, haemorrhage subsequent to oral anticoagu-
lant treatment (OAT) is the most common drug-related
side effect resulting in hospitalisation in public hospitals
in France (13% of such admissions, and 0.41% of the
3,137 admissions analysed). On the basis of these find-
ings, the AFSSAPS (French Agency for Health Product
Safety) has made the prevention of iatrogenic effects
related to OAT one of its priorities. Many of these events
are consequences of interactions between different drugs,
resulting in inappropriate doses [1-3].
Implementation of a system of support when prescrip-
tions are made out is likely to improve prescription prac-
tices and to decrease the frequency of side effects. It
should be possible to integrate a support tool into the
drug prescription system, by using nomograms to adjust
OAT doses.
Decision-making tools and appropriate practice
The efficiency of reminders issued at the time of prescrip-
tion has been demonstrated by a various studies [4-8].
These reminders can come in a paper, telephone [9] or
computer form. Hunt et al. [10] reviewed all studies (ran-
domised and quasi-randomised) evaluating the effect of
computer-based clinical decision support systems on
medical practice and treatment outcome. They showed
that these systems are effective for drug prescription pur-
poses and for the implementation of various medical
strategies [10]. We have demonstrated the efficiency of
reminders in the French situation, both in the form of
"paper" reminders [11] and in the form of computer-gen-
erated reminders [12]. Computer-generated reminders
appear the most promising given the development of
computer programs including prescription aids for hospi-
tal usage.
Several types of reminders can be issued at the time of pre-
scription [13]:
• simple, general information concerning the recommen-
dations that should be taken into account (non-specific or
non-personalised reminders),
• "check list": includes questions or a precise list of prac-
tices that the doctor must tick to show that it has been
done,
• reminders including clinical data concerning a specific
patient that must be taken into account for a given proce-
dure (personalised reminders).
The advantage of personalised reminders over non-per-
sonalised reminders has not been demonstrated in the lit-
erature. However, the production of personalised
reminders necessitates better integration of existing infor-
mation and is thus more expensive to develop. It is impor-
tant to determine whether this personalised tool results in
a better quality of care than non-personalised tools.
Several randomised clinical trials have tried to evaluate
decision support systems for the prescription of OAT, but
failed to draw any conclusions about their efficiency for
several reasons: heterogeneity and complexity of the sys-
tems evaluated, experimental designs difficult to apply
and not necessarily adapted, and too few patients
included [14-17].
Reminders issued at the time of prescription have been
shown to be effective by experimental studies, but the dif-
ficulties of maintaining the effectiveness of interventions
designed to improve clinical practices remains a major
problem. We evaluated the effect of an active decision
support system for the prescription of low molecular
weight heparin as prophylaxis for venal thrombosis in an
orthopaedic surgery department. In this study, the system
was and was not used during alternate periods. It showed
that such programs affect practices without affecting
learning [12]. Other authors have looked at the problem
of the routine use of computerised systems [18,19]. The
long-term use of a computer program to modify medical
practices necessitates a hospital information system that
ties in prescriptions and the results of medical tests, and
the continuous collection of indicators making it possible
to evaluate use and effect.
Georges Pompidou European Hospital (GPEH)
Organisation of the information system at GPEH
The hospital information system currently collates pre-
scriptions and results of biological tests and imaging pro-
cedures. Eight hundred computers, both laptops and fixed
posts, are used to in care procedures (in care departments
and medical offices).
The Dx-Care® program is at the centre of care delivery. It is
used by doctors and nurses:
• to prescribe laboratory examinations and imaging tests
for a patient,
• to visualise the results of laboratory tests,
• to establish and to consult nursing schedules,
• to archive a structured observation,
• to prescribe drugs.BMC Health Services Research 2004, 4:27 http://www.biomedcentral.com/1472-6963/4/27
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Dx-Care® is integrated with other applications to allow cir-
culation of information between departments, laborato-
ries and the pharmacy. Prescriptions for laboratory tests
are transmitted to the Netlab® program which manages
such tests (this program is used by all biochemistry, hae-
mostasis and immunology laboratories, etc.) The labora-
tories return the results using this same program, which
retransmits them to Dx-Care®. Furthermore, prescriptions
of drugs are transmitted to the Phedra program, which is
used by the pharmacy to manage prescriptions. The pre-
scription is validated by the pharmacy and this validation
is then transferred to Dx-Care®. The lab test prescription
facility has been available in the hospital information sys-
tem since 2000 and is used by all departments of the hos-
pital. The drug prescription facility has been implemented
later on, since January 2003, and its use is still increasing
(currently by half of the hospital departments).
The hospital information system thus allows to install
decision support systems that are activated whenever a
prescription is issued and routinely to collect evaluation
criteria of prescription practices. If possible and validated,
the use of the hospital information system to evaluate care
procedures will make it possible to collect data regularly,
and routinely to assess methods for the improvement of
care practices.
Organisation of quality assurance and system for recording 
undesirable events
With the aim of quality of care and preventing risks, the
hospital is developing a system, based on the Intranet net-
work, of declaration of undesirable events. This system
must be able to record all undesirable events and inci-
dents linked to the use of health products (drugs, medical
equipment, blood products, etc.) and care (e.g. falls, lost
files, bedsores, long waiting times) as well as those due to
the patient environment (building, security, malevolence,
etc.) and the job of health care professionals (accidental
exposure to blood, chemicals, radiation, etc.).
When a health care professional decides to report an
undesirable event, he or she must complete a dedicated
form available on the Intranet with all relevant informa-
tion. This incident form includes an item entitled "com-
plications associated with anti-coagulants". When the
doctor clicks on this item, a form specific to haemorrhagic
accidents following anti-coagulant treatment appears (see
form in appendix).
Prevention of thrombosis at GPEH
Among departments which already started to use the com-
puterised drug order entry system, several (cardiology and
vascular medicine departments) are heavy "consumers" of
anti-thrombosis drugs (see Table 1).
In 2001, a working group representative of all the hospital
departments described a group of procedures. This was
done by critically reading articles published in the litera-
ture. The procedures concerned the preventive and cura-
Table 1: Number of orders of fluindione during first semester 2004 in departments using computerized physician order entry system
Department January February March April May June Total
Internal Medicine* 45 50 58 53 21 227
Immunology 17 11 2 1 31
Nephrology 16 32 35 32 2 34 151
Vascular Medicine – Hypertension 71 23 46 23 46 16 225
Cardiovascular Surgery 2 129 143 140 90 64 568
Cardiology (1 unit)* 6 55 38 28 66 193
Total 106 246 331 291 219 202 1395
*Department which started to use the computerised physicians' drug order entry system in February 2004. Only one unit of the three in the 
Cardiology department started to use it.
Table 2: Nomogram for adjustment of fluindione from [23]
Day INR DOSE
D0 < 1,2 20 mg
D2 1–1,4 30 mg
1,5–1,7 25 mg
1,8–2,3 20 mg
2,4–3 15 mg
>3 10 mg
D4 <1,8 +10 mg
1,8–2,0 +4 mg
2,1–2,5 unchanged
2,6–3 dose > 20 mg: -5 mg
dose ≤ 20 mg: inchangée
>3 dose > 15 mg: -10 mg
dose ≤ 15 mg: -5 mg
D6 <2,3 +5 mg
2,3–3,5 unchanged
>3,5 -5 mgBMC Health Services Research 2004, 4:27 http://www.biomedcentral.com/1472-6963/4/27
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tive indications of anticoagulants (OAT and heparins) in
arterial thrombosis and venous thrombosis, and the way
in which patients receiving anticoagulants are monitored
and handled in cases of overdose. The procedure
concerning curative OAT included a nomogram for
adjusting doses of fluindione and warfarin based on previ-
ous doses and the INR (see Tables 2 and 3). These nomo-
grams are currently available on the hospital's intranet,
although they are not widely used. Their inclusion in a
computerised prescription aid could increase their
impact.
Study aims
Main aims
1. To evaluate the effect on the frequency of overanticoag-
ulation of the implementation in the computerised physi-
cian order entry system of two types of tool to adjust OAT
doses (one personalised and one non-personalised).
2. To assess any advantages of using the personalised tool
rather than the non-personalised tool.
Secondary aims
1. To evaluate the frequency of haemorrhagic accidents in
the context of the study.
2. To evaluate the feasibility of long-term implementation
of the intervention.
Methods
Experimental design
The study is an alternate time series experiment which
consists of three successive six-month periods (timed to
change with the changing of medical residents even
though they will not be the only prescribers). Each phase
will consist of:
• a two-month period without active support during
which evaluation criteria will be collected (period A),
• a two-month period with non-personalised active sup-
port (period B),
• a two-month period with personalised active support
(period C).
To limit the impact of a learning effect on appropriate
OAT management practice within the department over
time (possible for medical residents), the order of these
three periods was determined by using a Latin square plan
(see Figure). This experimental design can be considered
valid for an impact study in this context whereas a ran-
Table 3: Nomogram for adjustment of warfarin from [24]
Day INR dose (mg)
≤50 years 51–65 years 66–80 years >80 years
D0 <1,4 10 9 7,5 6
D1 ≤1,5 10 9 7,5 6
≥1,6 0,5 0,5 0,5 0,5
D2 ≤1,7 10 9 7,5 6
1,8–2,3 5 4,5 4 3
2,4–2,7 4 3,5 3 2
2,8–3,1 3 2,5 2 1
3 , 2 – 3 , 3 221 , 5 1
3,4 1,5 1,5 1 1
3 , 5 1110 , 5
3,6–4,0 0,5 0,5 0,5 0,5
> 4 0000
D3 ≤1,5 10–15 9–14 7,5–11 6–9
1 , 6 8765
1 , 7 – 1 , 8 7654
1 , 9 654 , 5 3 , 5
2,0–2,6 5 4,5 4 3
2,7–3,0 4 3,5 3 2,5
3,1–3,5 3,5 3 2,5 2
3,6–4,0 3 2,5 2 1,5
4,1–4,5 No pill, then 1–2 No pill, then 0,5–1,5 No pill, then 0,5–1,5 No pill, then 0,5–1,0BMC Health Services Research 2004, 4:27 http://www.biomedcentral.com/1472-6963/4/27
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domised controlled design is difficult to apply with just
one hospital [20].
Participants
Patients
This study will include all the patients who are prescribed
OAT for any indication and are hospitalised in clinical
care departments where physicians are using the hospital
information system to prescribe drugs.
The following table shows the number of INR examina-
tions prescribed by these departments in a three-month
period. It provides an estimation of the approximate pro-
portion of overdoses among the INR that exceeded 2,
which is supposed to be found in patients treated with
OAT in these units.
Physicians
All doctors authorised to prescribe drugs in the participat-
ing departments will be included in the study: residents
and fellows, registered and non registered university hos-
pital doctors. Each six-month period will coincide with an
internship semester.
Intervention
To prescribe a drug using Dx-Care®, the doctor selects the
required drug from an exhaustive list. This opens up a dia-
logue box in which the doctor types the dose, the fre-
quency of intake and the mode of administration. From
this window, it is possible to add a text comment or to
consult particular protocols that have been defined by the
departments.
It is planned to integrate two types of decision support
systems into the computerised prescription program:
1) non-personalised active system: when the drug is
selected a window automatically opens giving the
prescribing the nomogram for the adjustment of OAT
doses in the form of a table (see Tables 2 and 3).
2) personalised active system: when the drug is selected a
window automatically opens suggesting a dose recom-
mended according to the nomogram (taking into account
the doses previously received by the patient and the
patient's INR), together with a date for next INR control
and an explication.
Definition of endpoints
Overanticoagulation
Proportion of patient observation time with INR results >
4.5, assuming linear change of INRs.
Major haemorrhagic accidents
Intra-cranial haemorrhage or spontaneous haemorrhage
necessitating surgery or a transfusion or decreasing hae-
moglobin concentration by more than 2 g/dl.
Assessment of evaluation criteria
OAT overdose
The Netlab® application allows biological laboratories to
receive prescriptions and to return results. All of the INR
results can be extracted from the Netlab® database accom-
panied by information making it possible to identify the
patient, the treatment and dose received, the prescribing
doctor, the hospitalisation unit, the date the test was pre-
scribed. Data about overdoses can therefore be collected
systematically by regular database searches.
Study Design Figure 1
Study Design. A: Period without any decision support system; B: Period with non-personalised decision support system; C: 
Period with personalised decision support system
Phase 1 Phase 2 Phase 3
A B C B C C B A ABMC Health Services Research 2004, 4:27 http://www.biomedcentral.com/1472-6963/4/27
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Furthermore, the storage of the information in a compu-
terised tool will make it possible to determine previous
doses and INR results each time a drug is prescribed.
Haemorrhagic accidents
When a health care professional decides to declare an
undesirable event, he or she fills in a specific, pre-format-
ted form available on the Intranet. This form includes a
list of events that must be declared at the GPEH.
The declaration form includes an item entitled "complica-
tion of haemorrhagic accidents". When the doctor clicks
on this item, a specific form for the declaration of a haem-
orrhagic accident associated with anti-coagulant treat-
ment appears (see form in appendix).
Determination of sample size
The determination of the number of participants neces-
sary requires the definition of the statistical unit of inter-
est, information about the incidence of the evaluation
criteria in the study population and a hypothesis about
the efficiency of the intervention.
Statistical unit
In this study, the main aims are to guide each prescription
and to reduce the number of anti-coagulant overdoses:
the simplest statistical unit to study is therefore the INR
result. This unit will be used to calculate the sample size.
This choice is not, however, perfect and the efficacy results
will be presented using other indicators of the quality con-
trol of anti-coagulant treatments:
Given the low incidence of major haemorrhagic accidents
(not currently measured at the GPEH but probably below
1%), it is not possible in this study to estimate the number
of subjects necessary to demonstrate an effect of interven-
tion on the "haemorrhagic accident" endpoint. Recording
haemorrhagic accidents will give the frequency of such
accidents, which will then be used for realistic estimates of
power and sample size if further studies are carried out.
In previous studies evaluating the efficacy of tools to aid
the prescription of OAT, the unit considered was not
always the same, taking into account the number of INR
per patient and the time between INR measurements to
greater or lesser extents. The most recent studies consid-
ered the number of patient-days according to the method
described by Rosendaal [15,16,21]. This method can also
be used to calculate the rate of haemorrhagic events as a
function of the number of patient-days for a given range
of INR values.
We may also carry out an analysis for each prescribing
doctor given that the intervention targets doctors directly.
This will involve adjusting the effect of the intervention to
the fact that intra-physician variability is a priori lower
than inter-physician variability.
Number of INR measurements and predicted frequency of overdoses
During a six-month period (January to June 2004), 4 920
INRs were requested by the six departments which already
routinely use the computerized physician order entry sys-
tem. The frequency of overtreatment can approximately
be estimated from the percentage of INR > 4.5 among INR
>2. Among the 2620 INR > 2, 330 (12%) were higher than
4.5 (see Table 4). This frequency has been stable during
these six months but differed considerably between
departments (10% to 23%).
Hypothesis about the efficacy of the intervention
The number of INR tests necessary for a six-month period,
with an α risk of 5% and a power of 80%, for the compar-
ison of two percentages by classical methods (untreated
group half the size of the treated group), for a basal inci-
dence of the judgement criterion of 12% are and for the
following hypotheses on relative reduction of the risk
(RRR) of overdose, are:
• RRR 30%: 2500
• RRR 40%: 1300
• RRR 50%: 800
Table 4: Results of INR ordered during first semester 2004 in six departments
Number of valid results Number of INR > 2 (%) No. of INR > 4.5 (% of INR > 2)
Internal Medicine* 525 294 45 (15.3%)
Immunology 28 17 4 (23.5%)
Nephrology 182 109 18 (16.5%)
Vascular Medicine – Hypertension 560 273 28 (10.3%)
Cardiovascular Surgery 1224 633 98 (15.5%)
Cardiology (1 unit)* 2401 1294 137 (10.3%)
Total 4920 2620 330 (12.6%)BMC Health Services Research 2004, 4:27 http://www.biomedcentral.com/1472-6963/4/27
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• RRR 60%: 500
Carrying out approximately 5000 tests over six months
will make it possible to detect an intervention effect of less
than 30% in this period. The experimental design
includes three six-month periods and should thus ensure
adequate power.
Statistical analyses
Statistical analyses will be performed with the STATA sta-
tistical software (release 8, STATA corp, College station,
Tex, USA)
Standard statistical tests will be used to compare the base-
line characteristics of the departments and patients.
The main analysis concerns the effect of the intervention
on the number of dangerously high INRs. The analysis
will be carried out using a mixed effect analysis of variance
model, in which the effect linked to the period will be
considered fixed and that linked to the prescription tool
will be considered random [22].
Rosendaal's method will be used to analyse the number of
patient-days with INR over the target [21].
Regulatory aspects
According to French policy, this study was exempt from
medical ethics committee approval. The anti-coagulants
being evaluated are prescribed as recommended by clini-
cal studies validated within the GPEH. These recommen-
dations are available on the hospital's Intranet and are
thus accessible to all doctors. They conform to standard
practices. Neither the patients nor the doctors will be ran-
domised. The interventions are simply different means of
giving valid information to physicians. Using funding
from the PHRC (Hospital Clinical Research Program), we
carried out two research studies related to this project. In
the first (PHRC 95), an intervention aimed at modifying
the way in which emergency department doctors handle
ankle injuries, the study design was a randomised control-
led study and the randomisation unit was the hospital
[11]. In the second (PHRC 98), a computer-based deci-
sion-support system for the prevention of venous throm-
boses in orthopaedics, the experimental design was
identical to that of our present study [12]. In both cases,
the Ile de France branch of the Clinical Research
Delegation considered that the project was exempt from
medical ethics committee approval.
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